OR WAIT null SECS
Craigavon, N.I., UK, 7 September 2015 – Due to the overwhelming success experienced since the launch of its “Direct to Patient” shipping service for clinical trials throughout US and Canada in October last year, Almac has announced the expansion of this innovative service to EU countries.
The Direct to Patient offering guarantees all shipments are delivered direct to patients’ homes on time and without compromising product integrity, providing clinical trial sponsors a more cost effective approach to conduct their studies. Patient compliance, efficiency and experience is also improved as they are offered a flexible and convenient method to participate in trials that suit their personal circumstances.
This home delivery service further enhances the existing end-to-end clinical trial distribution service provided by Almac by co-ordinating all clinical trial (including temperature and non-temperature controlled) material shipments from clinical sites directly to patient’s homes within the European Union.
“The success of the service experienced to date across the US and Canada is testament to the upsurge in demand for a more patient-centric method of performing trials and we are pleased to be able to now offer this to European countries.” saidDonna Christopher, Almac’s Global VP Operations “Patient retention is often a significant concern associated with conducting clinical trials and Almac’s innovative Direct to Patient solution offers clear advantages to clinical trial patients and is yet another example of how we can ease the burden for sponsors.”